• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD).

作者信息

Sharma Ashish, Kumar Nilesh, Parachuri Nikulaa, Sharma Rohini, Bandello Francesco, Kuppermann Baruch D, Regillo Carl D

机构信息

Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India.

Department of Healthcare, The TIPS Global Institute, Coimbatore, Tamil Nadu, India.

出版信息

Eye (Lond). 2020 Aug;34(8):1310-1312. doi: 10.1038/s41433-020-0831-2. Epub 2020 Mar 4.

DOI:10.1038/s41433-020-0831-2
PMID:32132677
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7468355/
Abstract
摘要

相似文献

1
Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD).布罗鲁单抗与新生血管性年龄相关性黄斑变性（n-AMD）中的积液
Eye (Lond). 2020 Aug;34(8):1310-1312. doi: 10.1038/s41433-020-0831-2. Epub 2020 Mar 4.
2
A very effective treatment for neovascular macular degeneration.一种治疗新生血管性黄斑变性的非常有效的方法。
N Engl J Med. 2006 Oct 5;355(14):1493-5. doi: 10.1056/NEJMe068191.
3
Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.Brolucizumab 与阿柏西普治疗新生血管性年龄相关性黄斑变性患者的随机试验。
Ophthalmology. 2017 Sep;124(9):1296-1304. doi: 10.1016/j.ophtha.2017.03.057. Epub 2017 May 24.
4
Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.贝伐单抗与新生血管性年龄相关性黄斑变性：发病机制与治疗
Semin Ophthalmol. 2011 May;26(3):69-76. doi: 10.3109/08820538.2010.545100.
5
Intravitreal therapy in bilateral neovascular age-related macular degeneration.双侧新生血管性年龄相关性黄斑变性的玻璃体腔内治疗
Ophthalmology. 2014 Oct;121(10):2073-4. doi: 10.1016/j.ophtha.2014.05.007. Epub 2014 Jun 14.
6
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.HAWK 和 HARRIER：贝鲁珠单抗治疗新生血管性年龄相关性黄斑变性的 3 期、多中心、随机、双盲试验。
Ophthalmology. 2020 Jan;127(1):72-84. doi: 10.1016/j.ophtha.2019.04.017. Epub 2019 Apr 12.
7
[Introduction to the topic: Off-label use of bevacizumab in the treatment of neovascular age-related macular degeneration].[主题介绍：贝伐单抗在治疗新生血管性年龄相关性黄斑变性中的超说明书用药]
Ophthalmologe. 2006 Jun;103(6):461-2. doi: 10.1007/s00347-006-1351-6.
8
Managing neovascular age-related macular degeneration: a step into the light.
Med J Aust. 2007 Mar 19;186(6):276-7. doi: 10.5694/j.1326-5377.2007.tb00898.x.
9
Vascular-targeted photodynamic therapy in the treatment of neovascular age-related macular degeneration: Clinical perspectives.血管靶向光动力疗法治疗新生血管性年龄相关性黄斑变性：临床展望。
Photodiagnosis Photodyn Ther. 2015 Jun;12(2):161-75. doi: 10.1016/j.pdpdt.2015.03.007. Epub 2015 Apr 3.
10
Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.抗血管内皮生长因子疗法治疗新生血管性年龄相关性黄斑变性
Curr Opin Ophthalmol. 2009 May;20(3):158-65. doi: 10.1097/ICU.0b013e32832d25b3.

引用本文的文献

1
Usage of brolucizumab as treatment for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV): A narrative review.布罗鲁单抗用于湿性年龄相关性黄斑变性（AMD）和息肉状脉络膜血管病变（PCV）治疗的叙述性综述。
Medicine (Baltimore). 2025 Jun 6;104(23):e42666. doi: 10.1097/MD.0000000000042666.
2
Beyond Longer Intervals: Advocating for Regular Treatment of Neovascular AMD.超越更长间隔时间：倡导对新生血管性年龄相关性黄斑变性进行规律治疗。
J Clin Med. 2024 Dec 26;14(1):57. doi: 10.3390/jcm14010057.
3
Brolucizumab in patients with neovascular age-related macular degeneration: Real-life outcomes from a tertiary care eye hospital.Brolucizumab 治疗新生血管性年龄相关性黄斑变性：来自一家三级眼科医院的真实世界研究结果。
Indian J Ophthalmol. 2024 Nov 1;72(Suppl 5):S752-S757. doi: 10.4103/IJO.IJO_562_24. Epub 2024 Sep 10.
4
Functional and anatomical outcomes of brolucizumab for nAMD in a real-life setting.在真实环境下，brolucizumab 治疗 nAMD 的功能和解剖学结果。
Sci Rep. 2024 Jan 16;14(1):1441. doi: 10.1038/s41598-024-51315-0.
5
Relationship Between Drusen Height and OCT Biomarkers of Atrophy in Non-Neovascular AMD.非新生血管性年龄相关性黄斑变性中玻璃膜疣高度与 OCT 萎缩生物标志物的关系。
Invest Ophthalmol Vis Sci. 2022 Oct 3;63(11):24. doi: 10.1167/iovs.63.11.24.
6
Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice.布罗鲁单抗在实际临床实践中的短期疗效和安全性结果
Front Pharmacol. 2021 Nov 4;12:720345. doi: 10.3389/fphar.2021.720345. eCollection 2021.